XVIVO (XVIVO.ST)

Executive Summary

XVIVO is a Swedish medical technology company and world leader in machine perfusion for ex-vivo organ preservation, assessment, and transport. Its solutions address the critical shortage of transplantable organs by enabling more organs to be utilized and improving transplant outcomes. The company's portfolio includes systems for kidneys, livers, and lungs, with five commercial products in the market. XVIVO's technology has been shown to increase the pool of viable donor organs and enhance post-transplant results, positioning it as a key player in the organ transplant ecosystem. In recent years, XVIVO has focused on expanding its commercial footprint and advancing next-generation perfusion platforms. The company benefits from strong clinical evidence and growing adoption of machine perfusion globally. With increasing transplant waitlists and regulatory support for organ preservation technologies, XVIVO is poised for sustained growth. Its proprietary systems are becoming standard of care in leading transplant centers, and ongoing research aims to extend perfusion capabilities to other organs. The company's strong intellectual property and first-mover advantage underpin its competitive position.

Upcoming Catalysts (preview)

• Q3 2026FDA approval for XVIVO Heart Perfusion System70% success
• Q4 2026Positive Phase 3 trial results for liver perfusion with extended criteria donors65% success
• Q2 2027Commercial launch in China via partnership80% success